We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
Cap. Flow
-$505M
Cap. Flow %
-20.29%
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$84.9M
2
EHTH icon
eHealth
EHTH
+$41.7M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$35.2M
4
AGN
Allergan Inc
AGN
+$34M
5
ITMN
INTERMUNE INC
ITMN
+$26.9M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$87.6M
2
LH icon
Labcorp
LH
+$56.3M
3
MRK icon
Merck
MRK
+$27.1M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$26.4M
5
DGX icon
Quest Diagnostics
DGX
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 42.33%
2 Financials 2.57%
3 Technology 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
76
SCYNEXIS
SCYX
$39.3M
$4.56M 0.18%
+7,110
New +$4.98M
BSTC
77
DELISTED
BioSpecifics Technologies Corp.
BSTC
$4.55M 0.18%
+168,883
New +$4.4M
GWPH
78
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.29M 0.17%
+40,000
New +$2.78M
TTPH
79
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.18M 0.17%
+15,501
New +$3.33M
EGRX
80
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$4.08M 0.16%
284,653
– –
MRGE
81
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$3.77M 0.15%
1,658,696
+699,116
+73% +$1.59M
FMI
82
DELISTED
Foundation Medicine, Inc.
FMI
$3.69M 0.15%
137,021
-205,900
-60% -$5.22M
MDT icon
83
Medtronic
MDT
$105B
$3.49M 0.14%
54,800
-409,200
-88% -$24.9M
CYBX
84
DELISTED
CYBERONICS INC
CYBX
$3.43M 0.14%
+54,890
New +$3.34M
EXEL icon
85
CALL
Exelixis
EXEL
$14B
$3.39M 0.14%
1,000,000
+500,000
+100% +$1.73M
VIRX
86
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.3M 0.13%
2,408
+238
+11% +$276K
ITMN
87
CALL
DELISTED
INTERMUNE INC
ITMN
$3.25M 0.13%
73,500
-926,500
-93% -$34.1M
NSPH
88
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$3.16M 0.13%
100,000
– –
LMNS
89
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$2.91M 0.12%
+298,966
New +$2.78M
VYNT
90
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$2.36M 0.09%
1,393
-727
-34% -$1.38M
OCRX
91
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2M 0.08%
261,119
– –
PTN
92
Palatin Technologies
PTN
$14.3M
$1.98M 0.08%
1,600
– –
QCOR
93
DELISTED
QUESTCOR PHARMA INC
QCOR
$1.61M 0.06%
17,443
-1,022,422
-98% -$87.6M
AMED
94
DELISTED
Amedisys
AMED
$1.36M 0.05%
81,399
-357,601
-81% -$5.07M
SEM
95
DELISTED
Select Medical
SEM
$1.34M 0.05%
+158,913
New +$1.23M
SPPI
96
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.29M 0.05%
159,122
-1,106,253
-87% -$8.39M
AZN icon
97
AstraZeneca
AZN
$261B
$929K 0.04%
+12,500
New +$904K
AGRX
98
DELISTED
Agile Therapeutics
AGRX
$904K 0.04%
+52
New +$752K
NBIX icon
99
Neurocrine Biosciences
NBIX
$17.5B
$788K 0.03%
53,094
-24,900
-32% -$351K
OSIR
100
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$679K 0.03%
+43,445
New +$639K
2 3
4
5 6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2014 Portfolio in Review

As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.

  • Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
  • Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
  • Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
  • Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
  • Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.

Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.